Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2013

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2013		2012		2011
Antibiotic	$	9,167	$	6,724	$	6,101
Cardiovascular	25,876		18,142		12,553
Gallstone	6,114		5,991		5,370
Glaucoma	6,410		4,252		3,118
Gout	5,092		484		592
Migraine	5,418		5,971		8,654
Obesity	4,721		3,755		3,164
Pain Management	21,232		20,870		14,747
Thyroid Deficiency	57,978		50,849		47,051
Other	9,046		5,952		5,485
Total	$	151,054	$	122,990	$	106,835

Summary of products which accounted for at least 10% of net sales

	2013		2012		2011
Product 1	38	%	41	%	44	%
Product 2	10	%	8	%	5	%
Product 3	8	%	9	%	12	%

Summary of customers which accounted for at least 10% of net sales

	2013		2012		2011
Customer A	17	%	18	%	17	%
Customer B	12	%	11	%	10	%
Customer C	10	%	12	%	6	%